---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-004172"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:25:18.729346+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech shareholders approve issuance of up to 14.1M shares upon warrant exercise

## Summary
- Proposal 1 (issuing up to 14,089,672 shares upon warrant exercise) passed: 5,627,617 for, 2,945,357 against, 4,784,514 abstain.
- Proposal 2 (adjournment if needed) passed: 10,413,712 for, 2,866,539 against, 77,237 abstain.
- Quorum of 39.97% (13,357,488 shares) achieved at Special Meeting on February 14, 2024.
- Warrants were issued in a private placement that closed on December 26, 2023; shareholder vote was required under Nasdaq Listing Rules 5635(d).

## SEC filing metadata
- accession: 0001437749-24-004172
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774924004172/0001437749-24-004172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774924004172/mbrx20240214_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-004172
- JSON: https://secwatch.observer/filing/0001437749-24-004172.json
- Plain text: https://secwatch.observer/filing/0001437749-24-004172.txt

## Key facts
- Shareholder Votes
  Moleculin Biotech, Inc. shareholders approved Approval of issuance of up to 14,089,672 shares of common stock upon exercise of certain warrants as contemplated by Nasdaq Listing Rules 5635(d). at the 2024-02-14 meeting.
  - Outcome: passed
  - Meeting: 2024-02-14
  source text: Proposal 1. The NASDAQ Proposal - The Company's stockholders approved the issuance of up to 14,089,672 shares of common stock upon the exercise of certain warrants issued in a private placement that closed on December 26, 2023, as contemplated by Nasdaq Listing Rules 5635(d), as described in more detail in the Proxy Statement, by the following vote: Votes For Votes Against Abstain 5,627,617 2,945,357 4,784,514
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774924004172/0001437749-24-004172-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.